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ABSTRACT
Hepatocellular carcinoma (HCC) is one of the most common fatal malignancies 
but the molecular genetic basis of this disease remains unclear. By using genome-
wide methylation profiling analysis, we identified CLDN3 as an epigenetically 
regulated gene in cancer. Here, we investigated its function and clinical relevance in 
human HCC. CLDN3 downregulation occurred in 87/114 (76.3%) of primary HCCs, 
where it was correlated significantly with shorter survival of HCC patients (P=0.021). 
Moreover, multivariate cyclooxygenase regression analysis showed that CLDN3 was 
an independent prognostic factor for overall survival (P=0.014). Absent expression of 
CLDN3 was also detected in 67% of HCC cell lines, which was significantly associated 
with its promoter hypermethylation. Ectopic expression of CLDN3 in HCC cells could 
inhibit cell motility, cell invasiveness, and tumor formation in nude mice. Mechanistic 
investigations suggested through downregulation of GSK3B, CTNNB1, SNAI2, and 
CDH2, CLDN3 could significantly suppress metastasis by inactivating the Wnt/β-
catenin-epithelial mesenchymal transition (EMT) axis in HCC cells. Collectively, our 
findings demonstrated that CLDN3 is an epigenetically silenced metastasis suppressor 
gene in HCC. A better understanding of the molecular mechanism of CLDN3 in 
inhibiting liver cancer cell metastasis may lead to a more effective management of 
HCC patients with the inactivation of CLDN3.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most 
common malignancy in the world and the second leading 
cause of cancer death in Asia [1]. HCC is associated 
with multiple risk factors and is now recognized as a 
both genetic and epigenetic disease [2,3]. While the 
sequential accumulation of various genetic changes in 
hepatocarcinogenesis has been extensively studied, the 
contribution of epigenetic alterations to HCC development 
and progression has remained relatively poorly 
understood. Compelling evidence reveals that aberrant 
DNA methylation is a frequent event in HCC. Many 
studies showed that differentially methylated genes and 
CpG island methylator phenotype (CIMP) status in HCC 
were associated with clinicopathological features. Some 
commonly studied tumor suppressor genes (TSGs), such 
as RASSF1A, p16, SOCS1, GSTP1 and CDH1, have been 
found to be hypermethylated in HCC in a cancer-specific 
manner, suggesting that aberrant DNA methylation is an 
essential incident for hepatocarcinogenesis [4].
Using methylated DNA immunoprecipitation 
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Table 1: Association between CLDN3 mRNA expression and clinicopathologic characteristics of patients 
with HCC (n = 114)
Clinical features Number CLDN3 (-) CLDN3 (+) P-value 
Gender
Female
Male 
21
93 
17 (81.0%)
70 (75.3%) 
4 (19.0%)
23 (24.7%) 0.580 
Age (yrs)
<60
>60 
97
17 
73 (75.3%)
14 (82.4%) 
24 (24.7%)
3 (17.6%) 0.526 
HbsAg 
Negative
Positive 
18
90 
16 (88.9%)
66 (73.3%) 
2 (11.1%)
24 (26.7%) 0.159 
Serum AFP (ng/ml)
<400
>400 
59
48 
43 (72.9%)
37 (77.1%) 
16 (27.1%)
11 (22.9%) 0.619 
Tumor size (cm)
<5
>5 
48
62 
39 (81.2%)
44 (71.0%) 
9 (18.8%)
19 (29.0%) 0.214 
Cirrhosis
Absent
Present 
76
32 
57 (75.0%)
24 (75.0%) 
19 (25.0%)
8 (25.0%) 1.000 
Differentiation
Well differentiated (I)
Moderately differentiated (II)
Poorly differentiated (III-IV) 
15
45
46 
12 (80.0%)
34 (75.6%)
34 (73.9%) 
3 (20.0%)
11 (24.4%)
12 (26.1%) 
0.893 
Recurrence or Metastasis
Absent
Present 
57
54 
46 (80.7%)
38 (70.4%) 
11 (19.3%)
16 (29.6%) 0.205 
TNM stage (AJCC)
Early (I-II)
Advanced (III-IV) 
74
20 
55 (74.3%)
14 (70.0%) 
19 (25.7%)
6 (30.0%) 0.698 
Table 2:  Association of various factors with overall survival in 114 HCCs determined by COX regression model.
Univariate analysis Multivariate analysis
            Variable HRa(95%CIb) Pc HR(95%CI) P
Gender                     Male vs. Female 0.560(0.238-1.314) 0.183 - -
Age                          ≤60yr vs. >60yr 0.987(0.958-1.017) 0.388 - -
Tumor diameter       ≤5cm vs. >5cm 1.146(0.560-2.343) 0.709 - -
Cirrhosis                  Absent vs. Present 1.420(0.671-3.002) 0.359 - -
Differentiation         Well-Moderate vs. Poor 1.742(1.006-3.018) 0.048 1.785(0.981-3.248) 0.058
Recurrence               Absent vs. Present 3.337(1.491-7.470) 0.003 5.431(2.034-14.503) 0.001
TNM stage                Early vs. Advanced 2.315(1.013-5.290) 0.047 2.237(0.870-5.751) 0.095
CLDN3 expression   Reduced vs. Normal 0.308(0.107-0.885) 0.029 0.247(0.082-0.749) 0.014
aHR: hazard ratio for death. 
bCI: Confidence interval.
cP < .05 was considered statistically significant (in bold).
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coupled with DNA microarray (MeDIP-chip) analysis, we 
have identified that CLDN3 was preferentially methylated 
in cancer [5]. CLDN3 is located on Chromosome 
7q11.23 and belongs to a family of proteins involved 
in the formation and function of tight junctions (TJs). 
It’s well known that TJs function as the most topical 
barrier structure to fluid and cells in epithelial and 
endothelial cells. Disruption of TJs can trigger malignant 
transformation in a wide variety of epithelial cell types [6]. 
Early studies demonstrated that TJs were disorganized in 
HCC cells due to poor differentiation of the hepatocytes 
[7] and later studies found the disruption of TJ barrier 
could facilitate dissociated cancer cells to metastasize 
[8,9]. The backbones of TJs are mainly composed by 
occludins and claudins between adjacent cells. The 
dimerization of these trans-membrane proteins form a 
zipper-like structure to constrict the paracellular space to 
prevent solutes and water from passing through. The 24 
members from human CLDN protein family are expressed 
in a tissue-specific pattern. Recent studies have reported 
CLDN family members in a wide range of human cancers 
and found these types of proteins are also expressed 
in a tumor-specific manner [10]. For instance, low 
expression of CLDN1 has been reported to be associated 
with progression and metastasis in breast and prostate 
cancer [11,12] while the elevated expression of CLDN1 
exhibited structural and functional changes of epithelial to 
mesenchymal transition (EMT) –an important molecular 
event of metastasis [13]. Similarly, CLDN7 is highly 
expressed in renal cell carcinoma [14] but lost in invasive 
ductal carcinomas of the breast and in head and neck 
cancer [15,16]. These studies suggest the contribution 
of overexpression/loss of CLDNs in tumorigenesis may 
trigger different mechanisms and their expression pattern 
may be highly tissue-specific in different cancerous 
tissues. 
In this study, we initially examined the expression 
level of CLDN3 in human HCC cell lines and clinical 
HCC samples, as well as its correlation with promoter 
methylation status. Both in vitro and in vivo assays were 
used to study the tumor suppressive function of CLDN3. 
In addition, the tumor-suppressive mechanism of CLDN3 
and its clinical significance in HCC was also investigated.
RESULTS
CLDN3 is frequently downregulated in HCC
Semi-quantitative RT-PCR was initially used to 
study the mRNA expression status of CLDN3 in 9 HCC 
cell lines, 4 normal human liver tissues, and 52 primary 
HCCs and their paired adjacent normal tissues (Cohort 1). 
CLDN3 was significantly downregulated in 6/9 (66.7%) of 
HCC cell lines (HepG2, Hep3B, Huh7, Bel7404, SNU398, 
and PLC5) but was readily expressed in all 4 normal liver 
tissues (Fig. 1A). Expression of CLDN3 was observed in 
all 52 tested adjacent normal tissues, whereas reduced 
expression of CLDN3 was detected in 33/52 (63.5%) 
of primary HCCs (Fig. 1B). Protein expression level of 
CLDN3 was also studied by immunohistochemistry (IHC) 
staining in paraffin sections of 19 primary HCCs and their 
adjacent normal tissues obtained from Cohort 1 (Fig. 1C). 
Based on the score of staining, the average protein level 
of CLDN3 was significantly lower in HCC tumor tissues 
than that in adjacent normal tissues (1.2 vs. 2.4; P<0.0001; 
Fig.1D). Moreover, quantitative real-time PCR (qPCR) 
was performed to examine the mRNA expression level of 
CLDN3 in 114 primary HCCs and their adjacent normal 
liver tissues (Cohort 2). Similarly, downregulation of 
CLDN3 was detected in 87/114 (76.3%) of primary HCCs 
compared with their normal counterparts (defined as a 
2-fold decrease of CLDN3 expression in tumors) (Fig. 1E). 
CLDN3 is an independent predictor of poor 
survival in HCC patients
The correlation between CLDN3 expression status 
and clinicopathologic features of 114 HCCs was further 
evaluated, which was summarized in Table 1. The results 
showed that no correlation was observed between CLDN3 
downregulation and patient’s gender, age, HbsAg, serum 
AFP, tumor size, cirrhosis, tumor cell differentiation, 
recurrence and tumor stage. However, Kaplan-Meier 
survival analysis showed that the overall 5-year survival 
rate was significantly lower in informative HCC patients 
with CLDN3 downregulation (n=82, with a mean of 60 
months) than that in HCC patients with normal CLDN3 
expression (n=27, with a mean of 78 months) (P=0.021, 
Fig. 1F). By univariable analysis, downregulation of 
CLDN3 (P=0.029), presence of recurrence (P=0.003), 
poor differentiation (P=0.048), and advanced clinical stage 
(P=0.047) were significant negative prognostic factors for 
overall survival in HCC patients (Table 2). Nevertheless, 
multivariate analysis showed that downregulation of 
CLDN3 (P=0.014) and recurrence (P=0.001) were two 
independent prognostic predictors for HCC patients 
(Cohort 2) enrolled in this study (Table 2).
Promoter methylation of CLDN3 is correlated 
with its transcriptional inactivation 
To determine whether aberrant promoter 
methylation could contribute to downregulation of 
CLDN3 in HCC, we treated 3 HCC cell lines with absent 
expression of CLDN3 (HepG2, Hep3B, and PLC5) with 
the demethylating agent 5-Aza. The results showed 
expression of CLDN3 was restored in all 3 HCC cell 
lines examined (Fig. 2A), suggesting that inactivation 
of CLDN3 in HCC may be caused by its promoter 
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methylation. The methylation status of CLDN3 promoter 
was analyzed by MSP. Complete or partial methylation 
was detected in 6 HCC cell lines with absent expression 
of CLDN3 (HepG2, Hep3B, Huh7, Bel7404, SNU398, 
and PLC5), whereas no or weak methylation was detected 
in other 3 HCC cell lines (Huh1, Huh6, and SNU449) 
and 4 normal liver tissues with CLDN3 expression (Fig. 
2B). To further explore the methylation details of CLDN3 
in HCC, 6 HCC cell lines with different degrees of 
CLDN3 methylation were characterized by BGS. In line 
with the MSP results, the highest density of methylated 
CpG sites was found in Bel7404 and PLC5 cells with 
complete CLDN3 methylation, whereas no methylated 
CpG sites was found in Huh6, SNU449 and normal liver 
tissues with strong CLDN3 unmethylation (Fig. 2C). 
These results demonstrated that hypermethylation of the 
CLDN3 promoter was associated with its transcriptional 
repression. 
Fig.1: Downregulation of CLDN3 in HCC. (A) CLDN3 expression was frequently down-regulated in HCC cell lines (A) and 
primary HCCs (cohort 1) (B) detected by RT-PCR. For primary HCCs, expression of CLDN3 in tumor tissues (T) was compared with their 
paired nontumorous tissues (N). ACTB was used as a loading control. (C) Representative images of CLDN3 protein expression in a pair 
of HCC (right) and its adjacent normal tissue (left) determined by immunohistochemistry (IHC) with anti-CLDN3 antibody (brown). The 
slide was counterstained with hematoxylin. Original magnification, x200 (upper); x400 (lower). (D) CLDN3 protein expression level was 
indicated by IHC score according to the percentage of CLDN3 positive cells in primary HCC tumor tissues and their adjacent normal tissues 
(1,<20%; 2, 20-50%; 3,>50%). (E) CLDN3 expression was frequently down-regulated in primary HCCs (cohort 2) detected by qPCR. 
Dot plots represent the ΔCt values of CLDN3 (higher ΔCT values correspond to lower expression; Mean ± SEM; Mann-Whitney U test). 
(F) Kaplan-Meier curves for overall survival rate of patients with HCC according to the expression level of CLDN3. Green, patients with 
normal CLDN3 expression (n=27, mean survival time=78 months); Blue, patients with lower expression of CLDN3 (n=82, mean survival 
time=60 months, P=0.021)
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We next investigated the methylation frequency of 
CLDN3 promoter in 30 primary HCC tumors and their 
paired adjacent normal tissues by MSP. Methylation of 
CLDN3 was detected in 18/30 (60.0%) of the primary 
HCCs compared with their normal counterparts (Fig. 2D).
Ectopic expression of CLDN3 induces cobblestone-
like morphology change and suppresses foci 
formation in HCC cells
To determine if CLDN3 has tumor-suppressive 
function, stably CLDN3-expressing clones were 
established from HepG2 and Huh7 cells. CLDN3 gene and 
protein expression in these clones were confirmed by RT-
PCR and Western blot analyses (Fig. 3A,B). The CLDN3-
transfected HCC cells displayed an obvious morphological 
change compared with control cells. As shown in Fig. 3C, 
empty vector-transfected HCC cells grew in a normal 
state of monolayer culture while CLDN3-transfected 
cells formed cobblestone-like colonies (Fig. 3C). Ectopic 
expression of CLDN3 in these HCC cells also caused a 
significant decrease in cell foci formation. The number of 
foci formed in CLDN3-transfected cells were significantly 
reduced than those in empty vector-transfected cells (down 
to 48%-63% of vector control, P<0.01, Fig. 3D). However, 
no obvious difference was observed between CLDN3- and 
empty vector-transfected HepG2 and Huh7 cells by cell 
proliferation, cell cycle and cell apoptosis analyses (Fig. 
S1, P>0.05).
Metastasis suppressing ability of CLDN3 in HCC 
cells
Since CLDN3 is a tight junction (TJ) protein and 
disruption of TJ barrier could facilitate dissociated cancer 
cells to metastasize [9], we thus determine the metastatic 
Fig.2: CLDN3 promoter methylation status in HCC. (A) CLDN3 was restored after treatment with demethylating agent 5-aza-
2’deoxycytidine (Aza) in three HCC cell lines without endogenous CLDN3 expression. (B) Promoter methylation of CLDN3 in HCC cell 
lines and normal liver tissues was determined by methylation specific PCR (MSP). (C) Representative high-resolution methylation profiles 
obtained by bisulfite sequencing of BGS region (-117 to -2), comprised of 9 CpG sites in the CLDN3 promoter, in randomly selected 6 
HCC cell lines and 2 normal liver tissues. For each sequenced DNA sample, the percentage methylation of each CpG was defined as 
the percentage of methylated CpGs from 6-8 randomly sequenced clones. Black circle, 80-100% methylated CpG; White circle, 0-19% 
methylated CpG; Light grey circle, 20-39% methylated CpG; Grey circle, 40-59% methylated CpG; Dark grey circle, 60-79% methylated 
CpG. (D) Representative MSP results of CLDN3 in paired primary HCC (T) and adjacent normal (N) tissues.
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role of CLDN3 in HCC cells by wound-healing assays 
and Boyden chamber matrigel invasion assays. Ectopic 
expression of CLDN3 could significantly suppress the 
migration in CLDN3-transfectants compared with control 
cells in HepG2 (58.7% ± 1.0% vs. 74.1% ± 0.4%, P<0.01) 
and in Huh7 (5.0% ± 0.8% vs. 42.1% ± 0.7%, P<0.001; 
Fig. 4A). Similarly, CLDN3 could also significantly 
inhibit the invasion in CLDN3-transfectants compared 
with control cells by invasion assays in HepG2 (29.8% 
± 0.1% of control cells, P<0.001) and in Huh7 (52.2% 
± 0.2% of control cells, P<0.05; Fig. 4B). To further 
confirm the metastasis suppressing ability of CLDN3 in 
HCC cells, RNAi was used to knockdown endogenous 
CLDN3 expression in Huh6 cells. The result showed that 
siRNA against CLDN3 could significantly reduce CLDN3 
expression in Huh6 cells (Fig. S2). Twenty-four hours post 
siCLDN3 transfection, both wound-healing and invasion 
assays showed a significant increase of the cell migration 
(P<0.05, Fig. 4A3,4) and invasion ability (P<0.01, Fig. 
4B3,4) in CLDN3-knockdown Huh6 cells compared with 
control cells.
Ectopic expression of CLDN3 inhibits tumor 
growth in nude mice
To further explore the in vivo tumor suppressive 
ability of CLDN3, tumor formation in nude mouse was 
Fig.3: Morphological change and foci inhibition role of CLDN3 in HCC cells. Ectopic expression of CLDN3 in HCC cell lines 
(HepG2 and Huh7) was confirmed by RT-PCR (A) and western blot (B). (C) Representatives of cell morphology of CLDN3-expressing 
cells (HepG2-CLDN3/Huh7-CLDN3) and control cells (upper, original magnification ×100; lower, ×200). (D) Representative of foci 
formation in monolayer culture. Quantitative analyses of foci numbers were shown in the right panel. Values were the mean ± SD of at least 
three independent experiments. *P<0.05; independent Student’s t-test.
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tested by injection of Huh7-CLDN3 cells (n=5), while 
Huh7-Ctl cells (n=5) were used as controls. Within 17 
days, solid tumors were readily visible in right hind legs of 
all 10 mice injected with Huh7-CLDN3 cells and Huh7-Ctl 
cells, respectively (Fig. 5A). The mean tumor weight was 
significantly less in Huh7-CLDN3 inoculated nude mice 
than those in Huh7-Ctl cells injected nude mice (159.2 
± 34.2mg vs. 36.6 ±10.9mg, P<0.01, Fig. 5B). Moreover, 
the size of tumors caused by Huh7-CLDN3 cells was 
significantly smaller than tumors induced by Huh7-Ctl 
cells (tumor volume: 40.0 ±11.9mm3 vs. 7.10 ±3.22mm3, 
P<0.0001, Fig. 5C). These results demonstrated that 
CLDN3 has a strong tumor suppressive ability in vivo. 
CLDN3 inactivates WNT–EMT signaling 
pathways in HCC cells
To explore the mechanism underlying metastasis 
inhibition by CLDN3, deregulated genes involved in 
Wnt signaling between CLDN3-transfected HepG2 cells 
and control cells were determined by Wnt signaling 
pathway PCR array. From the 84 Wnt pathway related 
genes, 5 were decreased (GSK3B, CCDN1, CTNNB1, 
Fig.4: CLDN3 inhibits cell mobility and invasiveness in HCC cells. (A1-3) The effect of CLDN3 on cell migration was determined 
by wound-healing assay. During a period of 24h, the spreading speed of CLDN3-expressing cells (HepG2-CLDN3/Huh7-CLDN3) along 
the wound edge was slower than that in control cells (HepG2-Ctl/Huh7-Ctl, A1-2); while knockdown of CLDN3 in Huh6 cells by siRNA 
significantly promoted the cell mobility (A3). (A4) The percentage of open wound area was quantified in the right panel. (B1-3) Ectopic 
expression of CLDN3 significantly inhibited the invasion ability in HepG2 (B1) and Huh7 (B2) cells; while knockdown of CLDN3 by 
siRNA significantly promoted the invasion in Huh-6 cells (B3) by Boyden chamber matrigel invasion assay. (B4) The number of invaded 
tumor cells was quantified in the right panel. (*P<0.1, **P<0.05, ***P<0.01) 
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SLC9A3R1, and CSNK1D) and one (FZD3) was increased 
significantly (fold change >3, P<0.05) in HepG2-
CLDN3 cells compared with HepG2-Ctl cells (Fig. 
6A). Two significantly downregulated key modulators 
of the canonical Wnt pathway GSK3B (-5.28 fold) and 
CTNNB1 (-3.25 fold) were further verified by qPCR in 
CLDN3-transfected HepG2 and MHCC97H (a well-
known metastatic HCC cell line), as well as in CLDN3-
knockdown Huh6 cells (Fig. 6B). Furthermore, the 
correlation between CLDN3 expression and Wnt pathway 
induced molecules related to epithelial-mesenchymal 
transition (EMT) were also examined by qPCR. Among 
the 6 genes tested (CDH1, CDH2, CTNNB1, ZEB1, SNAI1, 
and SNAI2), one EMT-inducing transcription factor 
(SNAI2) and one mesenchymal marker (CDH2) showed 
significant negative correlation with CLDN3 expression 
in CLDN3- knockdown or overexpression HCC cells (Fig. 
6C). The protein level change of EMT markers in CLDN3-
knockdown/overexpression HCC cells were further 
confirmed by western blotting. Expression of E-cadherin 
(encoded by CDH1), β-catenin (encoded by CTNNB1), 
active β-catenin, mesenchymal marker N-cadherin 
(encoded by CDH2) and Slug (encoded by SNAI2) showed 
significant negative-correlation with CLDN3 expression in 
Huh6 and HepG2 cells (Fig. 6D), suggesting that CLDN3 
could act as a negative regulator of the WNT–EMT 
signaling pathways in hepatocarcinogenesis.
DISCUSSION
CLDN3 belongs to a family of proteins important 
in tight junction formation and function. Recently, it has 
become apparent that CLDN gene expression is frequently 
altered in several human cancers [17], its expression 
pattern and biological function are largely unrevealed in 
human liver cancer. Here, for the first time, we showed 
that CLDN3 was frequently downregulated in human 
liver cancer and its downregulation was significantly 
associated with poor survival of HCC patients. We 
found that reduced expression of CLDN3 was caused 
by promoter hypermethylation in HCC cells. This is 
in line with previous studies demonstrating that the 
expression level of CLDN3 was epigenetically regulated 
by promoter methylation in esophageal cancer [18] and 
ovarian cancer cells [19]. The expression of other claudin 
family members, such as CLDN1 in podocyte [20] and 
breast cancer [21] and CLDN4 in bladder cancer [22], 
has also been reported to be regulated through promoter 
hypermethylation. 
It has been widely accepted that disruption of TJ 
barrier is a common event in various human cancers and 
loss of TJ function is correlated to cancer progression 
and metastasis [23]. Disassembly of TJs can cause loss of 
cell polarity and increased cell invasiveness [23, 24]. The 
claudin family proteins are known to form the “backbone” 
of TJs between cells and their expression profile in 
Fig.5:  In vivo tumor suppressive role of CLDN3 in HCC. (A) Representative examples of tumors formed in nude mice following 
injection of CLDN3-expressing Huh7 cells (lower panel) and Huh7-Ctl cells (upper panel). (B) Histogram shows quantitative result of the 
tumor weight from Huh7-CLDN3 group and control group. Value are mean ± SD. P=0.007. (C) Tumor growth curves of CLDN3-expressing 
Huh7 cells (Huh7-CLDN3) in nude mice were compared with Huh7-Ctl cells by tumor xenograft experiment. The average tumor volume of 
Huh7-CLDN3 cells vs Huh7-Ctl cells was expressed as mean ± SD in 5 inoculated sites for each group of cells. **P<0.0001. 
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different tissues are highly tissue specific [25, 26]. CLDN3 
was uniformly expressed in the normal rat liver [27] and 
an increased expression of CLDN3 was observed in liver 
regeneration 2-3 days after hepatectomy [28], suggesting 
the potentials of CLDN3 in maintaining normal liver 
function and regeneration of fully polarized normal 
hepatocytes. In this study, we observed a cobblestone-
like epithelial morphology and cellular aggregation in 
cultured CLDN3- overexpression HCC cells. In contrast, 
control HCC cells without endogenous CLDN3 displayed 
a spindle shape, fibroblast-like mesenchymal morphology, 
and pronounced cellular scattering in monolayer culture, 
suggesting the inactivation of CLDN3 in HCC might 
be related to EMT and cancer invasion/metastasis. 
Previous studies reported that morphologic changes 
from cobblestone-like to fibroblast-like occurred in cells 
undergoing EMT, which is a key process for epithelial 
cancer cells to survive following detachment from 
basement membrane and migrate through the extracellular 
matrix (ECM) to enable cancer cells to “seed” to adjacent 
tissues or to colonize to distal part of the body through 
circulation [29,30]. A recent study also demonstrated that 
both CLDN3 and CLDN4 regulated EMT in ovarian cancer 
cells [31]. Similar to previous study that CLDN3 has no 
significant effect on ovarian cancer cell proliferation and 
cell cycle progression [32], our results also found that 
ectopic expression of CLDN3 in HCC cells with absent 
CLDN3 expression did not show any change in the cell 
proliferation rate, cell cycle distribution, and apoptosis 
in vitro. However, we observed a significant inhibitory 
role of CLDN3 in liver cancer cell migration and 
invasion. Moreover, CLDN3 could significantly inhibit 
HCC tumor growth in vivo. Notably, overexpression of 
CLDN3 did not affect cell proliferation in vitro but inhibit 
tumor growth in vivo. One possibility is that CLDN3 is 
a transmembrane protein in the tight junction barrier, 
which may render its growth inhibition potential in vivo 
in response to extracellular signals originating from the 
tumor microenvironment. These findings suggested that 
CLDN3 may play a critical role in maintenance of normal 
TJ function to prevent cells from dispersion but not in 
regulation of pathways that determine the cell fate such as 
cell cycle or apoptosis. 
To better elucidate the invasive and metastatic 
mechanisms of CLDN3, the effect of CLDN3 
overexpression or depletion on Wnt signaling pathway and 
Fig.6: CLDN3 inactivates Wnt-EMT signaling in HCC cells. (A) The scatter plot of PCR array analysis graphs the expression 
level (2-ΔCt) of genes related to Wnt signaling pathway in the HepG2-CLDN3 cells versus the HepG2-Ctl cells. The black line indicates 
fold changes (2-ΔΔCt) of 1. The pink lines indicate a fold change of 3 in gene expression. (B, C) Histograms represent the fold up or 
downregulation of GSK3B and CTNNB1 (B), as well as SNAI2 and CDH2 (C) in CLDN3-overexpression or knockdown HCC cells by 
qPCR. (D) Expressions of epithelial markers E-cadherin, β-catenin, active β-catenin and mesenchymal markers Vimentin and N-cadherin 
were compared by Western blotting analysis between CLDN3-overexpression or knockdown HCC cells. GAPDH was used as loading 
control.
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EMT was investigated. Using qPCR analyses, we found 
the metastasis suppressor role of CLDN3 in HCC cells 
was associated with the inhibition of Wnt-EMT activity 
through downregulation of GSK3B (encodes GSK3β), 
CTNNB1 (encodes β-catenin), SNAI2 (encodes Slug), and 
CDH2 (encodes N-cadherin) by qPCR analyses. Both 
GSK3β and β-catenin are key molecules of the canonical 
Wnt pathway implied in many human cancers [33]. 
Although it remains controversial whether GSK3β is a 
“tumor suppressor” or “tumor promoter” in regulation of 
neoplastic transformation and tumor progression, GSK3β 
expression level was found to be higher in liver tumors 
than in normal liver tissues in a mouse model of hepatic 
carcinogenesis [34]. A recent study also showed that both 
GSK3β and β-catenin expression level were significantly 
reduced with a concomitant reduction of metastatic 
capability and expression of Wnt signaling pathway 
targeted genes in HCC cell line SMMC-7721 subjected 
to anti-cancer drug treatment [35]. Slug is a critical EMT-
inducing transcription factor and its activity was also 
regulated by canonical Wnt signaling [36]. N-cadherin 
is a mesenchymal marker which can be induced by Slug 
[37]. Upregulation of N-cadherin is also associated with a 
heightened invasive potential in many cancers including 
HCC [38-41]. Further study by western blot analyses 
confirmed the changes of β-catenin Slug, N-cadherin in 
CLDN3 overexpressed or depleted HCC cells. Moreover, 
the epithelial marker E-cadherin was increased, whereas 
the mesenchymal marker vimentin was downregulated 
in CLDN3-overexpressing cells. All of these results 
postulated that epigenetic silencing of CLDN3 in HCC 
might fail to suppress the β-catenin mediated Wnt pathway 
to promote EMT. 
In conclusion, we demonstrated that CLDN3 is an 
epigenetically silenced metastasis suppressor gene and 
plays a crucial role in the development and progression 
of HCC. CLDN3 downregulation was an independent 
prognostic factor for poor survival of HCC. A better 
understanding of the molecular mechanism of CLDN3 
in inhibiting liver cancer cell metastasis may lead to a 
more effective management of HCC patients with the 
inactivation of CLDN3.
METHODS
Cell lines and cell culture 
Ten human HCC cell lines (HepG2, Hep3B, Huh1, 
Huh6, Huh7, SNU398, SNU449, PLC5, Bel7404, and 
MHCC97H) were used in this study. Cell lines were 
maintained in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin-streptomycin. 
Patients and tissue samples
Two cohorts of clinical HCC tissue samples were 
investigated in this study. Cohort 1 includes 52 pairs of 
primary HCC tumors and their adjacent nontumorous 
tissues, which were collected immediately after surgical 
resection prior to any other therapeutic intervention at 
the Third Affiliated Hospital of Sun Yat-Sen University 
(Guangzhou, China). All samples were confirmed by 
histology. Informed consent was given by all of the 
patients. The study protocol was approved by the Clinical 
Research Ethics Committee of the Sun Yat-Sen University 
of Medical Sciences. Cohort 2 includes cDNA samples 
synthesized from 114 pairs of primary HCC tumors and 
their adjacent nontumorous tissues, which were kindly 
provided by Prof. XY Guan at the University of Hong 
Kong [42]. Human normal liver tissue RNA samples 
were purchased commercially (Stratagene, La Jolla, CA). 
Clinical data of Cohort 2 patients included in this study are 
detailed in Supplementary Table 1.
RT-PCR and real-time quantitative PCR (qPCR)
Total RNA was extracted by Direct-zol RNA 
MiniPrep kit (Zymo Research, Irvine, CA) from cell 
pellets or tissues. cDNA was synthesised by MultiScribe 
Reverse Transcriptase (ABI, Calsbad, CA). RT-PCR was 
performed with TaKaRa Taq Hot Start Version kit (Takara, 
Japan). Q-PCR was performed with Power SYBR Green 
PCR Master Mix reagent (ABI). 10ng cDNA template 
and 3pmol of primer pairs were applied in each 10μl 
PCR reaction. All qPCR primers used in this study were 
acquired from online primer database (medgen.ugent.be) 
and purchased commercially (Invitrogen, Calsbad, CA).
5-aza-2’-deoxycytidine (5-Aza) treatment
1x107 cells of each HCC cell line were seeded into 
100mm culture dishes and incubated overnight. 5-Aza 
(Sigma, St. Louis, MO) was then added into the cell 
culture at a final concentration of 2μM and incubated for 
96h. After 5-Aza treatment, the cells were harvested for 
RNA extraction and further analysis.
Bisulfite treatment and promoter methylation 
analysis 
Genomic DNA was extracted by QIAamp DNA 
Mini Kit (Qiagen, Valencia, CA) and 1 mg of DNA 
was bisulfite-modified by EZ DNA Methylation-Gold 
Kit (Zymo Research) following the manufacturer’s 
instructions. The bisulfite-modified DNA was then 
amplified by methylation-specific PCR (MSP) using 
primer pairs that specifically amplify either methylated 
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or unmethylated sequences of the CLDN3 gene. Bisulfite 
genomic sequencing (BGS) was performed to assess 
the methylation levels of 9 CpG sites spanning from 
-117 to -2 of the CLDN3 promoter region in HCC cell 
lines. Nucleotide sequences of the primers were listed in 
Supplementary Table 2.
CLDN3 cloning and lentivirus transduction
The full-length CLDN3 cDNA was obtained by 
RT-PCR using normal human liver cDNA as template. 
The PCR product was cloned into pcDNA3.1/V5-His-
TOPO TA vector (Invitrogen) and the authenticity of the 
sequence was verified by sequencing (BGI, Shenzhen, 
China). The pCDNA3.1-CLDN3 plasmid was then sub-
cloned into lentiviral eukaryotic expression vector pLVX-
ZsGreen1-PGK-Puro by commercially available service 
(Genomeditech, Shanghai, China) and the lentivirus 
particles were packaged by GM easy lentivirus packaging 
kit (Genomeditech) in 293FT cells and harvested after 48h 
incubation by following the manufacturer’s instructions. 
The lentiviral particles containing either empty vector or 
CLDN3 construct were transducted into HCC cell lines 
and the cells were then subjected to puromycin (2μg/ml) 
selection for at least 2 weeks to establish stable CLDN3-
expressing clones. 
RNA Interference 
Small interfering RNA (siRNA) (100 nM) against 
CLDN3 or a scrambled sequence (RiboBio Co. Ltd. 
Guangzhou, China) was transfected into cells in 6-well 
plates using jetPRIME transfection reagent (Polyplus-
Transfection, Illkirch-Graffenstaden, France) according to 
the manufacturer’s instructions. At 48h after transfection, 
the effects of gene silencing were measured via qPCR and 
western blot analysis. 
Foci formation assay
1x103 of CLDN3-transfected or empty vector-
transfected HCC cells were seeded in 6-well plates and 
selected with puromycin (2μg/ml) for 7 days. Surviving 
colonies were then visualized by 1% crystal violet staining 
and colonies with no less than 50 cells/colony were 
counted.
Cell proliferation assay
Cell proliferation was determined by xCELLigence 
RTCA DP system (Roche, Kaiseraugst, Switzerland). 
Briefly, 5x103 HCC cells were seeded into each well of the 
16-well E-plate supplied by 200μl DMEM culture medium 
in triplicates. The xCELLigence system was then used to 
monitor the cell growth rate continuously for 72h.
Cell cycle and apoptosis analysis
Cell cycle distribution and apoptosis were examined 
by flow cytometry. For cell cycle analysis, after 12h of 
synchronization by serum starvation, the CLDN3-
transfected HCC cells were incubated with 10% fetal 
bovine serum (FBS) for 24h. Cells were fixed in 70% 
ethanol and stained with 50 μg/mL propidium iodide (BD 
Pharmingen, San Jose, CA). The cells were then sorted by 
FACSCalibur (BD Biosciences, San Jose, CA) and cell-
cycle profiles were analyzed by WinMDI v. 2.9 software 
(Scripps Research Institute, La Jolla, CA). Apoptosis 
was assessed by flow cytometry after staining with 
FITC conjugated Annexin V and 7-amino-actinomycin 
(7-AAD) following the manufacturer’s instruction (BD 
Biosciences).
Migration assay and invasion assay
For cell migration assay, cells were seeded into 
24-well plate (2x105/well) and incubate overnight. After 
starving in serum free medium for 24h, the cell layer was 
wounded using a sterile tip and the medium was then 
replaced by DMEM containing 10% FBS. The crosses in 
the wells were photographed by microscopy at time point 
0 hour and 24 hours. The percentages of open wound 
area were calculated using TScratch software [43] kindly 
provided by Dr. Johnny Koon at the Chinese University of 
Hong Kong. The experiment was performed in triplicate. 
For invasion assay, cells were starved with serum free 
medium for 24h before the assay. Cells (1×105) were 
suspended in 0.5ml serum-free medium and loaded on 
the upper compartment of invasion chamber coated with 
Matrigel (BD Biosciences). The lower compartment was 
filled with complete medium as chemoattractant. After 
24h, invasive cells were fixed, stained, and counted under 
a microscope. Triplicate independent experiments were 
performed.
Immunohistochemistry (IHC)
IHC staining was performed using the standard 
streptavidin-biotin-peroxidase complex method. Briefly, 
paraffin sections of HCC tissues were deparaffinized, 
blocked with 10% normal goat serum for 10min, 
and incubated with anti-CLDN3 polyclonal antibody 
(Invitrogen, 1:800 dilution) overnight at 4°C. The tissue 
section was then incubated with biotinylated goat anti-
rabbit immunoglobulin at a concentration of 1:75 at 37°C 
for 30min. The status of CLDN3 expression was assessed 
by two independent investigators without prior knowledge 
of clinicopathologic data. The extent of CLDN3 staining 
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was scored manually by assigning the percentage of 
positive tumor cells (0, none; 1, <40% of positive staining 
cells; 2, 40-70% of positive staining cells; 3, >70% of 
positive staining cells).
In vivo tumorigenicity 
1x107 of stable CLDN3-overexpression cells and 
control cells were injected subcutaneously into the dorsal 
right flank of 6-week-old male Balb/c nude mice (n=5 
per group), respectively. Tumor diameter was measured 
every 3 days from the 5th day after inoculation for 17 
days. The tumor volume was calculated by the formula 
V = 0.5×L×W2. All experimentations on animals 
were approved by the Animal Experimentation Ethics 
Committee of the Chinese University of Hong Kong.
RT2 profiler PCR array
Total RNA extraction was performed using the 
Direct-zol RNA MiniPrep kit as described above. The 
first-strand cDNA synthesis was performed using a RT2 
First-Strand cDNA Synthesis kit (Qiagen) and 1000 ng of 
total RNA was processed for the human WNT signaling 
pathway PCR array (SABiosciences, PAHS-043Z, 
Frederick, MD). Alterations in mRNA transcript levels 
between HepG2-CLDN3 and HepG2-Ctl groups were 
initially analyzed using SABiosciences webportal software 
(http://www.sabiosciences.com/pcrarraydat aanalysis.php). 
Fold changes and P values were calculated using Student’s 
t-test. A P value<0.05 with a fold change greater than 3.0 
were considered to be a significant dysregulation. 
Western blot
Total protein was extracted and the concentrations 
were determined by Bradford Protein Assay (Bio-Rad, 
Hercules, CA). 30μg of protein from each sample was 
separated on 8~12% SDS-PAGE and transferred onto 
polyvinylidene fluoride membrane (Bio-Rad). Blots 
were detected by incubation with antibodies to CLDN3 
(Invitrogen), total/active β-catenin, E-cadherin, Vimentin, 
N-cadherin, and GAPDH (Cell Signaling, Danvers, MA).
Statistics
Statistical analysis was performed with the SPSS 
standard version 16.0 (Chicago, IL) or GraphPad Prism 
5 (GraphPad Software, La Jolla, CA). Results expressed 
as mean ± SD were analyzed using the Student t test. 
The difference of CLDN3 expression between tumor and 
adjacent normal tissues were compared using the Mann-
Whitney U test. Correlation between CLDN3 expression 
and clinicopathological features were determined by 
Pearson’s Chi-square test. Overall survival curves was 
assessed by the Kaplan-Meier method and compared by 
the log-rank test. Relative risks of cancer-related death 
associated with CLDN3 expression status were estimated 
by univariate analyses. Multivariate survival analysis 
was carried out on all parameters that were found to be 
significant on univariate level using the Cox regression 
model. P value less than 0.05 was considered statistically 
significant. 
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